|
|
 |
|
Viewing report
|
|
|
|
Risk Sharing and Innovative Contracting with CROs
Business Insights, Feb 2011, Pages: 132
CROs are seeking greater upside from royalties and other opportunities to participate in profits. Meanwhile, drug makers have an interest in reducing upfront drug development costs, and reducing the financial risks of product failure.
More sponsors and CROs are entering into innovative relationships where risk is shared more fully between the two companies, while profits from successful projects are also shared. Key types of agreements include preferred vendors, functional service providers (FSPs), risk sharers, alliance partners, drug licensors, joint venture partners and contract research alliance partners.
Scope of this research
- Identify the benefits and challenges of risk sharing & innovative contracting agreements and structure more successful deals.
- Analyze compensation and pricing issues in risk sharing agreements, so that negotiations may be more fruitful.
- Evaluate the different types of risk sharing and innovative contracting agreements.
- Learn from detailed case studies of the activities of leading drug developers and CROs.
- Gain insight into to optimal conditions for risk sharing and innovative contracting agreements and their outlook to 2016.
Research and analysis highlights
Risk sharing/innovative contracting agreements are becoming more popular, although many companies are not yet able to structure effective relationships. Successful agreements can be extremely beneficial for both drug developers and CROs, however, unsuccessful relationships can significantly impact either or both companies’ businesses.
The leading CROs tend to be more flexible and willing to partner than less experienced CROs. The number of risk sharing/innovative contracting agreements is expected to continue to expand strongly, although some types of relationships will be utilized more than others.
Risk sharing/innovative contracting agreements with offshore CROs will experience particularly strong growth as the drug development industries in China and India expand.
Key reasons to purchase this research
- Why are risk sharing agreements between drug developers and CROs becoming more popular?
- What are the key considerations in such agreements for both parties?
- Which types of risk sharing agreements are most popular?
- Which CROs & drug developers are most active in risk sharing?
- What are the typical benefits of risk sharing agreements?
|
|
|
|
